Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment By Ogkologos - June 16, 2026 66 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Heartburn Medications Pulled From Shelves Because They May Cause Cancer January 13, 2020 Creating a shared vision to detect cancer earlier October 15, 2020 Protecting Your Skin From the Sun All Year: Why It’s Important... January 8, 2021 Divarasib in Combination with Cetuximab Demonstrates a Manageable Safety Profile and... December 20, 2023 Load more HOT NEWS EMA Recommends Extension of Indications for Dabrafenib and Trametinib Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,... The future of research: meet three of our scientists working on... Glucose Control Key in Reducing Cancer Risk for People with Type...
